Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 104-108

  Tuohimaa, Pentti ^a   Tenkanen, Leena ^b   Ahonen, Merja ^a   Lumme, Sonja ^b   Jellum, Egil ^c   Hallmans, Göran ^d   Stattin, Pär ^e   Harvei, Sverre ^f   Hakulinen, Timo ^g   Luostarinen, Tapio ^g   Dillner, Joakim ^h   Lehtinen, Matti ⁱ   Hakama, Matti ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b Helsinki Heart Study   (Finland)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e UMEÅ UNIVERSITY   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g FINNISH CANCER REGISTRY   (Finland)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

25(OH) vitamin D3; Prostate cancer; Serum bank

Indexed keywords

CALCIFEDIOL; CALCITRIOL; ENZYME; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FINLAND; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITOSIS; NORWAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SWEDEN; TARGET CELL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

ADULT; CALCIFEDIOL; CASE-CONTROL STUDIES; FINLAND; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORWAY; PROSTATIC NEOPLASMS; RISK; SWEDEN; VITAMIN D DEFICIENCY;

EID: 0345256390     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11375     Document Type: Article

References (45)

1. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 1990;10:1307-11.
2. Ylikomi T, Laaksi I, Lou YR, Martikainen P, Miettinen S, Pennanen P, Purmonen S, Syvala H, Vienonen A, Tuohimaa P. Antiproliferative action of vitamin D. Vitam Horm 2002;64:357-406.
3. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.
4. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000;86:40-6.
5. 3. Cancer Res 1992;52:515-20.
6. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58:277-88.
7. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:10-7.
8. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140:1205-12.
9. 3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 1999;59:4023-9.
10. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1α ,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997;6:727-32.
11. Majeski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S. Vitamin D is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol Symp Proc 1996;1:97-101.
12. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467-72.
13. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94:1867-75.
14. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
15. Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW, Strange RC. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001;358:641-2.
16. Ruijter E, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20:22-45.
17. Feldman D, Zhao XY, Krishnan AV. Vitamin D and prostate cancer. Endocrinology 2000;141:5-9.
18. Freedman DM, Dosemeci M, McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 2002;59:257-62.
19. Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet 2001;357:1764-6.
20. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000;60:305-8.
21. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J 2001;48:543-9.
22. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
23. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7:385-90.
24. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-10.
25. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 1995;6:235-9.
26. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:121-6.
27. Nomura AMY, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick FM. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-32.
28. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842-56.
29. 3-induced growth inhibition. Cancer Res 2001;61:2852-6.
30. 3. Cancer Epidemiol Biomarkers Prev 1998;7:391-5.
31. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
32. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
33. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect 1995;103(Suppl 3):85-8.
34. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
35. Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ, Platz EA. Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 2002;60:1118-23.
36. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998;9:559-66.
37. Willis MS, Wians FH. The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin Chim Acta 2003;330:57-83.
38. Grant WB. Calcium, lycopene, vitamin D and prostate cancer. Prostate 2000;42:243.
39. Holick MF. Photobiology of vitamin D. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. San Diego: Academic Press, 1997. 33-9.
40. 3 analogues in breast cancer cells. Cancer Res 1996;56:2789-94.
41. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60.
42. Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev 1998;17:353-60.
43. Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D, Virtamo J. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000;11:859-67.
44. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-6.
45. Walczak J, Wood H, Wilding G, Williams T Jr, Bishop CW, Carducci M. Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urology 2001;57:81-5.